Short Communication - Journal of Clinical Research and Pharmacy (2023) Volume 6, Issue 1
The stereoselective metabolism of carvingilol in liver microsomes is predicted to be cleared by the liver
Carole Taylor *
Department of Biochemistry & Biophysics, University of California San Francisco, San Francisco, United States
- *Corresponding Author:
- Carole Taylor
Department of Biochemistry & Biophysics
University of California San Francisco, San Francisco
Received: 01-Feb-2023, Manuscript No.AAJCRP-23-89470; Editor assigned: 02-Feb-2023, PreQC No.AAJCRP-23-89470(PQ); Reviewed: 16-Feb-2023, QC No.AAJCRP-23-89470; Revised: 18-Feb-2023, Manuscript No.AAJCRP-23-89470(R);Published: 20-Feb-2023, DOI: 10.35841/aajcrp-6.1.133
Citation: Taylor C. The stereoselective metabolism of carvingilol in liver microsomes is predicted to be cleared by the liver. J Clin Res Pharm. 2023;6(1):133
Carvedilol is a commonly used beta-blocker in the treatment of hypertension and heart failure. Its metabolism in the liver has been studied extensively, and it has been shown that carvedilol is predominantly metabolized by cytochrome P450 enzymes, primarily CYP2D6 and CYP2C9. The metabolism of carvedilol is stereoselective, with the enantiomer being metabolized more rapidly than the R(+)-enantiomer. Liver microsomes, which are subcellular fractions of liver cells, have been used to study the metabolism of carvedilol. In vitro studies have shown that the metabolism of carvedilol in liver microsomes is stereoselective, with the enantiomer being metabolized more rapidly than the R(+)-enantiomer. This stereoselective metabolism is due to the fact that the active site of the CYP2D6 enzyme, which is responsible for the metabolism of carvedilol, has a specific orientation that favors the metabolism of the enantiomer. The clearance of carvedilol from the body is primarily through hepatic metabolism, with approximately 60-70% of the drug being metabolized in the liver. The stereoselective metabolism of carvedilol in liver microsomes indicates that the liver is the major organ responsible for the metabolism of carvedilol, and that the clearance of the drug is primarily through hepatic metabolism.
Stereoselective metabolism, carvedilol, liver microsomes, liver, clearance.
Carvedilol is a beta-adrenergic blocking drug with alpha1-adrenergic blocking and antioxidant properties that is used to treat hypertension, heart failure, and angina. The stereoselective metabolism of carvedilol in liver microsomes is an important factor that determines its pharmacokinetic properties, including clearance from the body. The metabolism of carvedilol involves several cytochrome P450 (CYP) enzymes, which can metabolize the two enantiomers of carvedilol differently. The purpose of this essay is to explain the stereoselective metabolism of carvedilol in liver microsomes and how this affects its clearance by the liver. Carvedilol is a chiral drug, meaning it exists in two enantiomeric forms, (R)-carvedilol and (S)-carvedilol. These enantiomers have different pharmacological properties and are metabolized by different CYP enzymes. (S)-Carvedilol is primarily metabolized by CYP2D6, while (R)-carvedilol is metabolized by CYP2C9 and CYP3A4 .
The stereoselective metabolism of carvedilol in liver microsomes refers to the preferential metabolism of one enantiomer over the other by specific CYP enzymes. CYP2D6 is a highly polymorphic enzyme, which means that different individuals have different levels of enzyme activity. Poor metabolizers of CYP2D6 have decreased metabolism of (S)-carvedilol, which results in higher plasma concentrations of (S)-carvedilol compared to (R)-carvedilol. This can result in differences in the efficacy and safety of carvedilol treatment among individuals, depending on their CYP2D6 genotype. In contrast, extensive metabolizers of CYP2D6 metabolize (S)-carvedilol more efficiently, resulting in lower plasma concentrations of (S)-carvedilol and potentially reducing the risk of adverse effects. CYP2C9 and CYP3A4 are also highly polymorphic enzymes, but their contribution to the metabolism of carvedilol is less well understood compared to CYP2D6. Both CYP2C9 and CYP3A4 can metabolize (R)-carvedilol, but their relative contribution to the metabolism of (R)-carvedilol is unclear [2,3].
Studies have shown that (R)-carvedilol can also undergo glucuronidation and sulfation in addition to oxidation by CYP enzymes. The contribution of these conjugation reactions to the overall metabolism of (R)-carvedilol is also unclear. The metabolism of carvedilol in liver microsomes is important for its clearance from the body. Clearance refers to the rate at which a drug is removed from the body, and is determined by a combination of factors, including metabolism, excretion, and distribution. The hepatic clearance of carvedilol is primarily determined by the metabolism of (S)-carvedilol by CYP2D6, which is the major metabolic pathway for (S)-carvedilol. The clearance of (R)-carvedilol, on the other hand, is less well understood and may involve multiple metabolic pathways, including oxidation by CYP2C9 and CYP3A4 and conjugation reactions. The clearance of carvedilol can also be affected by drug interactions, which can alter the activity of CYP enzymes and result in changes in the pharmacokinetics of carvedilol. For example, drugs that inhibit CYP2D6, such as fluoxetine and paroxetine, can increase the plasma concentration of (S)-carvedilol and potentially increase the risk [4,5].
- Iwaki M, Niwa T, Nakamura Y, et al. Relative contribution of rat CYP isoforms responsible for stereoselective metabolism of carvedilol. J Toxicol Sci. 2018;43(1):59–63.
- Niwa T, Shiraga T, Ishii I, et al. Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005;28(9):1711–6.
- Bartsch W, Sponer G, Strein K, et al. Pharmacological characteristics of the stereoisomers of carvedilol. Eur J Clin Pharmacol. 1990;38(2):S104-7.
- Komura H, Iwaki M. Usefulness of hepatocytes for evaluating the genetic polymorphism of CYP2D6 substrates. Xenobiotica. 2005;35(6):575–87.
- Fujimaki M, Shintani S, Hakusui H. Stereoselective metabolism of carvedilol in the rat. Use of enantiomerically radiolabeled pseudoracemates. Drug Metab Dispos. 1991;19(4):749–53.